Cantor Fitzgerald maintains Overweight on Neurocrine Bio, $170 target

On Tuesday, Neurocrine Biosciences Inc. (NASDAQ:NBIX), currently trading at $120.69 with a market capitalization of $12 billion, maintained its Overweight stock rating and a $170.00 price target, as confirmed by Cantor Fitzgerald. The decision follows a review of the company’s first-quarter results for 2025 and its recent 10-Q filing. According to InvestingPro data, the stock appears undervalued based on its Fair Value analysis. Cantor Fitzgerald’s analysts have adjusted their financial model for Neurocrine Biosciences, reducing the terminal growth rate from 3% to 2.5%. Despite this adjustment, they have slightly increased their estimates for future revenues from Neurocrine’s drugs Ingrezza and Crenessity.

The analysts expressed a level of uncertainty regarding which of the company’s assets would contribute to or maintain long-term growth. Nevertheless, the firm stands by its Overweight rating and the $170 price target for Neurocrine Biosciences’ shares. InvestingPro analysis shows the company maintains a "GREAT" financial health score of 3.65, with analyst targets ranging from $115 to $192 per share. The Overweight rating suggests that Cantor Fitzgerald believes the stock will outperform the average total return of the stocks in the analyst’s industry coverage universe over the next 12 to 18 months.

Neurocrine Biosciences specializes in neurological and endocrine-related diseases and has a portfolio of products and pipeline candidates, including Ingrezza (valbenazine), which is used to treat adults with tardive dyskinesia, and Crenessity (opicapone), a once-daily, oral selective catechol-O-methyltransferase inhibitor. The company has demonstrated strong performance with 24.8% revenue growth over the last twelve months, generating $2.36 billion in revenue.

The updated estimates and maintained stock rating are based on the latest financial data and market conditions. The company’s financial performance and product pipeline remain key factors in Cantor Fitzgerald’s analysis.

Investors and stakeholders in Neurocrine Biosciences will likely monitor the company’s progress closely, especially regarding the performance of Ingrezza and Crenessity, as well as any developments in the company’s pipeline that could impact its long-term growth trajectory. For deeper insights into NBIX’s valuation and growth prospects, including 8 additional ProTips and comprehensive financial analysis, check out the detailed Pro Research Report available on InvestingPro. The firm’s maintained Overweight rating and price target reflect their current view of the stock’s potential performance in the market.

In other recent news, Neurocrine Biosciences reported first-quarter earnings for 2025, with a diluted non-GAAP EPS of $0.70 and revenue of $572.6 million, surpassing Wall Street’s expectations of $0.54 EPS and $559.6 million in revenue. UBS analyst Ashwani Verma raised the company’s stock target to $152, maintaining a Buy rating, while Stifel kept its Buy rating with a $166 target, both highlighting strong performance from Neurocrine’s products, Ingrezza and Crenessity. RBC Capital Markets also adjusted its price target to $145, citing unexpected commercial momentum and maintaining an Outperform rating. BMO Capital Markets increased the target to $115, acknowledging Crenessity’s impressive sales but expressing caution regarding future challenges for Ingrezza. Piper Sandler, meanwhile, reduced its target to $154, maintaining an Overweight rating and noting the potential for increased prescription growth for Ingrezza. The firm’s analysts highlighted that Crenessity’s early success could ease pressure on Ingrezza’s growth expectations. These developments reflect a mixed but generally positive outlook from analysts on Neurocrine Biosciences’ recent performance and future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.